PDE5: Began Phase I testing in the U.K. with partner Glaxo Wellcome

ICOS Corp. (ICOS), Seattle Product: PDE5, inhibitor of cyclic nucleotide phosphodiesterase Indication: Congestive heart failure, angina, and erectile dysfunction Status: Began Phase I testing in the ...